You Position: Home > Paper
The significance of detecting IgH rearrangement in patients with diffuse large B-cell lymphoma using real-time flourescence quantitative PCR
( views:444, downloads:36 )
- Author:
- No author available
- Journal Title:
- JOURNAL OF LEUKEMIA & LYMPHOMA
- Issue:
- 4
- DOI:
- 10.3760/cma.j.issn.1009-9921.2007.04.002
- Key Word:
- 淋巴瘤,弥漫大细胞;基因重排,B淋巴细胞,重链;聚合酶链反应
Abstract： 目的 探讨荧光染料标记的实时定量PCR方法检测弥漫大B细胞淋巴瘤(DLBCL)IgH基因重排的可行性和临床意义.方法 44例DLBCL患者的57份骨髓标本用于检测IgH基因重排.Namalwa细胞系作阳性对照,U-937细胞系作阴性对照.SYBR Green荧光染料标记的实时荧光定量PCR方法检测IgH基因重排CDRⅢ.β-actin作内参照,对IgH基因重排相对定量.结果 分析融解曲线可以确定IgH基因重排产物的特异性.荧光定量PCR检测IgH基因重排的阳性率分别为63.2%.Ⅰ、Ⅱ期患者IgH基因重排表达量中位数为0,Ⅲ、Ⅳ期患者IgH基因重排表达量中位数为0.35,两组患者之间差异有统计学意义(P=0.018).LDH值高于正常组,IgH基因重排表达量为0.39,LDH值低于正常组,IgH基因重排表达量为0.01,两组之间差异有统计学意义(P=0.046).结论 荧光染料标记的定量PCR方法可用于DLBCL的骨髓微小残留病变的检测.检测骨髓IgH基因重排,可以协助分期.
- [1]林法迎,侯健,谭龙益,等.实时定量PCR监测多发性骨髓瘤患者自体造血干细胞移植后微小残留病[J].2003,(5).
- [2]Shiramizu B,Morris E,Sabesan V,etc.Assessment of minimal residual disease in childhood non-hodgkin lymphoma by polymerase chain reaction using patient-specific primers.[J].2003,25(2).
- [3]K, Maloum,O, Pritsch,G, Dighiero.Minimal residual disease detection in B-cell malignancies by assessing IgH rearrangement.[J].1997,39(3).
- [4]Ito S,Masuda T,Satoh T,etc.Development of consensus fluorogenically labeled probes of the immunoglobulin heavy-chain gene for detecting minimal residual disease in B-cell non-Hodgkin lymphomas.[J].2003,94(10).
- [5]M, Nakao,J W, Janssen,T, Flohr,etc.Rapid and reliable quantification of minimal residual disease in acute lymphoblastic leukemia using rearranged immunoglobulin and T-cell receptor loci by LightCycler technology.[J].2000,60(12).
- [6]Masuda T,Tarusawa M,Yashima A,etc.Quantitative assessment of contaminating tumor cells in autologous peripheral blood stem cells of B-cell non-Hodgkin lymphomas using immunoglobulin heavy chain gene allele-specific oligonucleotide real-time quantitative-polymerase chain reaction.[J].2003,27(10).
- [7]Bolton AE,Gooley LT,Norman JE,etc.Significance of molecular marker-positive cells after autologous peripheral-blood stem-cell transplantation for non-Hodgkin's lymphoma.[J].1995,13(5).
- [8]Weisenburger DD,Lynch JC,Armitage JO,etc.Autologous transplantation for aggressive non-Hodgkin's lymphoma: results of a randomized trial evaluating graft source and minimal residual disease.[J].2002,20(9).
- [9]Landt O,Beyermann B,Eckert C,etc.Potential of LightCycler technology for quantification of minimal residual disease in childhood acute lymphoblastic leukemia.[J].2000,14(2).
- [10]Munakata Y,Ichinohasama R,Ishizawa K,etc.Detection of clone-specific immunoglobulin heavy chain genes in the bone marrow of B-cell-lineage lymphoma after treatment.[J].2004,203(3).